Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Article in English | IMSEAR | ID: sea-25241

ABSTRACT

Oral prostaglandin E2 tablets (group I) and iv Oxytocin (group II) were evaluated in 120 randomly selected women subjected to induction of labour. In group I, 60 women received oral prostaglandin E2 tablets in incremental doses from 0.5-1.5 mg hourly, depending upon the parity and Bishop score of the patient. Group II women received oxytocin iv in 5 per cent dextrose, starting at a rate of 2 mU/min and gradually increasing to a maximum of 64 mU/min. Overall success rate in group I (prostaglandin E2) and group II (intravenous oxytocin) was 85 and 93.3 per cent respectively (P greater than 0.05). In the favourable group (Bishop score 6-13) the induction delivery interval (IDI) for group I and group II was 8.86 h and 7.95 h respectively (P greater than 0.05), while in the unfavourable group (Bishop score less than or equal to 5), the IDI for the respective groups were 13.42 h and 10.11 h (P less than 0.05). Side effects with prostaglandin E2 were mostly mild gastrointestinal ones. A significantly higher incidence of foetal distress was observed with intravenous oxytocin (15%) as compared to prostaglandin E2 (3.33%). Oral prostaglandin E2 was thus found to be a better alternative to intravenous oxytocin in multiparous women with favourable Bishop score (greater than 6) and in those in whom fluid retention is to be avoided (e.g., conditions like toxemias, renal disease).


Subject(s)
Administration, Oral , Adult , Dinoprostone , Drug Evaluation , Female , Humans , Infusions, Intravenous , Labor, Induced/methods , Oxytocin , Pregnancy
5.
J Indian Med Assoc ; 1972 Apr; 58(8): 285-7
Article in English | IMSEAR | ID: sea-105002
6.
Indian Pediatr ; 1970 Oct; 7(10): 542-6
Article in English | IMSEAR | ID: sea-11983

Subject(s)
Adult , Birth Weight , Humans
7.
Indian J Pediatr ; 1970 May; 37(268): 185-91
Article in English | IMSEAR | ID: sea-84733
SELECTION OF CITATIONS
SEARCH DETAIL